lundi 8 janvier 2018

Onco Actu du 8 janvier 2018

1. Biologie

Microbiota-wide association studies and PD-1 immunotherapy [NIHilist's Immunology]

New cancer model shows genomic link between early-stage and invasive breast cancer types [MD Anderson Cancer Center]

Effort to identify tumor-specific antigens: The University Industrial Complex study results [NIHilist's Immunology]

Bacteria and Cancer: Another Connection [In the Pipeline]

Which Cancers are Most Survivable and Why? [The Darwin Cancer Blog]

Fusobacterium May Help Colorectal Cancer Grow and Spread [NCI]

2.10 Etiologie - Alcool

Alcohol and cancer: This is how booze damages DNA inside cells [Cancer Research UK]

Drinking alcohol raises risk of cancer by snapping DNA, scientists find [The Telegraph]

How alcohol damages stem cell DNA and increases cancer risk [Reuters]

Only one in 10 Britons know alcohol causes cancer, survey finds [The Guardian]

2.6 Etiologie - Environnement

Monsanto wins support from 11 U.S. states in California cancer dispute [Reuters]

3.1 Prévention - Tabac

Use of non-cigarette tobacco products tied to teen smoking [Reuters]

4. Dépistage, diagnostic et pronostic

Too much screening has misled us about real cancer risk factors, experts say [STAT]

4.10 Dép., diag. & prono. - Poumon

Lung cancer screening works better when individual risk factors are taken into account, study says [LA Times]

4.12 Biopsies liquides

British cancer test firm signs deal to break into China [The Telegraph]

5. Traitements

Scientists are combining drugs and radiotherapy, hunting for better results [Cancer Research UK]

Drug Combination Improves Outlook for Some Patients with Chronic Lymphocytic Leukemia [NCI]

Age may be a factor in facial skin cancer treatment [Reuters]

Experts Forecast Cancer Research and Treatment Advances in 2018 [Cancer Research Catalyst]

5.10 Traitements - Essais

Unique Trial Aims to Decrease Early Deaths in Patients with Rare Leukemia [NCI]

5.12 Immunothérapies

'Is Ian cured? Maybe': the astonishing cancer treatment of Australia's chief scientist [The Guardian]

5.12.2 Immunothérapies - CAR-T

2017 Was the Year of Gene-Therapy Breakthroughs [MIT Technology Review]

5.12.4 Immunothérapies - Essais

Virus could treat brain tumours by boosting immune system [Institute of Cancer Research]

Viruses may boost immunotherapy in brain and breast cancer [Cancer Research UK]

Immune boosting virus could be used to treat brain tumors [Reuters]

5.12.5 Immunothérapies - Pharma

World renowned immunologist, professor Eric Vivier, joins Innate Pharma as Chief Scientific Officer [Innate Pharma]

5.12.7 Immunothérapies - vaccins

BioNTech raises mammoth $270M A round, nearing $1B mark as investors continue a love affair with mRNA [EndPoints]

5.2 Pharma

FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma [Seattle Genetics]

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer [Novartis]

Celgene's Revlimid fails lymphoma trial, and it's more than a data shortfall: analyst [FiercePharma]

5.2.1 Pharma - Partenariats

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment [Roche]

Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca [Myriad]

Pfizer lines up an $830M alliance with Arvinas on protein degradation [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies [Celgene]

After 2nd Bet on Familiar Drug, Impact Bio Lands $1B Celgene Buyout [Xconomy]

J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact Biomedicines [FierceBiotech]

Roche Bets $1.7B More on Precision Oncology With Ignyta Deal [Xconomy]

Roche to buy Ignyta for $1.7 billion [PharmaTimes]

Roche lines up at the FDA’s 10-yard line with $1.7B Ignyta buyout [EndPoints]

5.2.3 Pharma - économie

Enterome gets €32M, Bristol-Myers Squibb backing, for cancer work [FierceBiotech]

Made in China: New and Potentially Lifesaving Drugs [NY Times]

5.3.4 Traitements - AMM (FDA, EMA)

FDA expands use of Amgen's blockbuster drug [Reuters]

Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label [Novartis]

FDA clears stereotactic radiotherapy system for use in treating breast cancer [FDA]

FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response [FDA]

New drug approvals hit 21-year high in 2017 [Reuters]

5.4 Traitements - Economie

Humira’s Best-Selling Drug Formula: Start at a High Price. Go Higher. [NY Times]

How does cost sharing rules influence drug prices in Germany? [Healthcare Economist]

NICE to reassess Pfizer’s leukaemia drug Besponsa [PharmaTimes]

6. Lutte contre les cancers

Proton beam cancer treatment to start in Manchester in 2018 [BBC News]

Resolutions of a Cancer Doctor [NY Times]

7 Key Cancer Trends For 2018 [Forbes]

Precision Medical Treatments Have A Quality Control Problem [NPR]

6.1 Observation

Cancer Mortality in the U.S. Continues Decades-Long Drop [ACS]

Cancer Deaths Continue a Steep Decline [NY Times]

When Cancer Strikes Twice [NY Times]

Cancer survival rates are up [The Telegraph]

6.11 Patients

When the Lung Cancer Patient Climbs Mountains [NY Times]

6.6 Publications

Germany vs Elsevier: universities win temporary journal access after refusing to pay fees [Nature]

Editor quits journal over pay-for-expedited peer-review offer [Science]

6.7.1 Bioinformatique

Deep learning sharpens views of cells and genes [Nature]

Microsoft, Google invest in precision medicine startup DNAnexus [Healthcare IT News]

6.8 Communication

Representing a “revolution”: how the popular press has portrayed personalized medicine [Genetics in Medicine]